Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

• ClinicalTrials.gov Identifier: NCT05315700
• Recruitment Status: Recruiting
• First Posted: April 7, 2022
• Last Update Posted: May 10, 2024
• Sponsor: ORIC Pharmaceuticals
• Information provided by (Responsible Party): ORIC Pharmaceuticals

Tracking Information

• First Submitted Date: March 24, 2022
• First Posted Date: April 7, 2022
• Last Update Posted Date: May 10, 2024
• Actual Study Start Date: March 10, 2022
• Estimated Primary Completion Date: March 2025 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: April 6, 2022)

• Recommended Phase 2 Dose (RP2D) [ Time Frame: 12 months ]
  RP2D as determined by interval 3+3 dose escalation design
• Maximum plasma concentration (Cmax) [ Time Frame: 28 Days ]
  PK of ORIC-114
• Time of maximum observed concentration (Tmax) [ Time Frame: 28 Days ]
  PK of ORIC-114
• Area under the curve (AUC) [ Time Frame: 28 Days ]
  PK of ORIC-114
• Apparent plasma terminal elimination half-life (t1/2) [ Time Frame: 28 Days ]
  PK of ORIC-114

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: April 12, 2022)

• Objective response rate (ORR) [ Time Frame: 36 months ]
  Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
• Duration of response (DOR) [ Time Frame: 36 months ]
  Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
• Clinical benefit rate (CBR) [ Time Frame: 36 months ]
  Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
• Progression-free survival (PFS) [ Time Frame: 36 months ]
  Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
• Intracranial response rate (CR and/or PR) [ Time Frame: 36 months ]
  Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
• Intracranial progression-free survival (PFS) [ Time Frame: 36 months ]
  Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

Original Secondary Outcome Measures (submitted: April 6, 2022)

• Objective response rate (ORR) [ Time Frame: 36 months ]
  Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
• Duration of response (DOR) [ Time Frame: 36 months ]
  Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
• Clinical benefit rate (CBR) [ Time Frame: 36 months ]
  Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
• Progression-free survival (PFS) [ Time Frame: 36 months ]
  Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
• Intracranial response rate (CR and/or PR) [ Time Frame: 36 months ]
  Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
• Intracranial progression-free survival (PFS) [ Time Frame: 36 months ]
  Modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
• Official Title: An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
• Brief Summary: The purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to patients with advanced solid tumors harboring an EGFR or HER2 alteration.

Detailed Description

ORIC-114 is a brain penetrant, selective, orally bioavailable, irreversible small molecule inhibitor designed to target EGFR and HER2 alterations, making it a promising therapeutic candidate for development in patients whose tumors harbor these alterations, including those with CNS metastases.

This is a first-in-human, open-label, single arm, multicenter, dose escalation study of ORIC-114 as a single agent (Part I), followed by dose optimization (Part II) to establish the recommended phase 2 dose (RP2D) and antitumor activity of ORIC-114 in patients with advanced solid tumors harboring an EGFR or HER2 alteration who have exhausted available treatment options. After the optimal RP2D has been determined, Phase 2 will be initiated via protocol amendment to add one or more expansion cohorts of patients with specific tumor types, treatment history, and/or expression of a specific biomarker to evaluate the antitumor activity of ORIC-114.

After completion of Part I dose escalation, Part III, a dose escalation study of ORIC-114 in combination with chemotherapy (carboplatin-pemetrexed) may be initiated to establish the RP2D and/or MTD and antitumor activity for the combination (US sites only).

• Study Type: Interventional
• Study Phase: Phase 1; Phase 2

Study Design

Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Interval 3+3 dose escalation design

Masking: None (Open Label)
Primary Purpose: Treatment

• Condition: Solid Tumors

Intervention

• Drug: ORIC-114
  ORIC-114 oral daily
• Drug: Chemotherapy drug
  21 days for up to 4 cycles
  Other Name: carboplatin and pemetrexed

Study Arms

• Experimental: Dose Escalation and Dose Optimization
  ORIC-114 dosed orally on a continuous once daily dosing regimen in 28-day cycles.
  Intervention: Drug: ORIC-114
• Experimental: Combination Dose Escalation
  ORIC-114 dosed orally on a continuous once daily dosing regimen in 21-day cycles.
  Interventions:

  • Drug: ORIC-114
  • Drug: Chemotherapy drug

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: May 8, 2024): 350
• Original Estimated Enrollment (submitted: April 6, 2022): 42
• Estimated Study Completion Date: March 2026
• Estimated Primary Completion Date: March 2025 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed locally advanced or metastatic solid tumor with a documented EGFR or HER2 exon 20 insertion mutation or atypical EGFR mutation as determined by any nucleic acid-based diagnostic testing method, or HER2 amplification/overexpression as determined by an immunohistochemistry (IHC) or an in situ hybridization (ISH) test

  1. Part I Dose Escalation (CLOSED) Any solid tumor with

     • EGFR exon 20 insertion mutation
     • HER2 exon 20 insertion mutation
     • Atypical EGFR mutations (NSCLC only) (Appendix 8)
     • HER2 amplification or overexpression (HER2+)
     • Previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable

  2. Part I Extension (ONGOING)

     • Cohort IA: Patients with HER2+ breast cancer previously received and progressed on or after available standard therapies and for whom additional standard therapy is considered unsuitable or intolerable
     • Cohort IB: NSCLC patients with EGFR exon 20 insertion mutation previously treated with chemotherapy and amivantamab
     • Cohort IC: Treatment-naïve NSCLC patients with EGFR exon 20 insertion mutation

  3. Part II Dose Optimization (ONGOING): NSCLC patients with

     • Cohort IIA: EGFR exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was contraindicated. Additionally, patients must be naïve to an EGFR exon 20 targeted agent, ie, must have declined or be ineligible for all available exon 20 targeted therapies with proven benefit
     • Cohort IIB: HER2 exon 20 insertion mutation, patients must have received platinum-based chemotherapy or other chemotherapy regimen if platinum- based chemotherapy was contraindicated. Additionally, patients must be naïve to a HER2 exon 20 targeted TKI
     • Cohort IIC: Atypical EGFR mutation, patients may have received a prior EGFR TKI
• Agreement and ability to undergo pretreatment biopsy
• Measurable disease according to RECIST 1.1
• CNS involvement, which is either previously treated and controlled, or untreated and asymptomatic
• ECOG performance status of 0 or 1
• Adequate organ function

Exclusion Criteria:

• Known EGFR T790M mutation

• Leptomeningeal disease and spinal cord compression

  -- Except if LMD has been reported radiographically on baseline MRI, but is not suspected clinically by the Investigator; the subject must be free of neurological symptoms of LMD

• History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months
• Past medical history of interstitial lung disease (ILD), drug induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD
• Known, symptomatic human immunodeficiency virus (HIV) infection
• Known active infection requiring treatment or history of hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients positive for HBsAg but normal HBV DNA level are allowed.
• Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes
• Any other concurrent serious uncontrolled medical, psychological, or addictive conditions

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Contacts

Contact: ORIC Clinical; 650-388-5600; clinical@oricpharma.com

• Listed Location Countries: Australia, Canada, Hong Kong, Korea, Republic of, Poland, Taiwan, United Kingdom, United States

Administrative Information

• NCT Number: NCT05315700
• Other Study ID Numbers: ORIC-114-01
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: ORIC Pharmaceuticals
• Original Responsible Party: Same as current
• Current Study Sponsor: ORIC Pharmaceuticals
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Pratik S. Multani, MD, MS; ORIC Pharmaceuticals

• PRS Account: ORIC Pharmaceuticals
• Verification Date: May 2024